Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.
CEA
Granulysin
colon carcinoma
immunotoxin
scFv
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
19
03
2019
revised:
01
07
2019
accepted:
03
07
2019
entrez:
25
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors. Previous work demonstrated the therapeutic effect of intratumoral injection of recombinant granulysin using
Identifiants
pubmed: 31646080
doi: 10.1080/2162402X.2019.1641392
pii: 1641392
pmc: PMC6791445
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1641392Informations de copyright
© 2019 Taylor & Francis Group, LLC.
Références
Tumour Biol. 2004 Jan-Apr;25(1-2):91-8
pubmed: 15192316
PLoS One. 2009;4(4):e5381
pubmed: 19401768
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74
pubmed: 9435250
Nat Microbiol. 2016 Oct 17;2:16189
pubmed: 27748768
Cell. 2014 Jun 5;157(6):1309-23
pubmed: 24906149
Microb Cell Fact. 2014 Aug 12;13:116
pubmed: 25112455
Clin Cancer Res. 2016 Jan 15;22(2):310-8
pubmed: 26350263
Am J Pathol. 2018 Aug;188(8):1736-1743
pubmed: 29870741
J Clin Oncol. 2012 May 20;30(15):1822-8
pubmed: 22355053
Br J Cancer. 1999 May;80(5-6):922-6
pubmed: 10360677
Leukemia. 2018 Aug;32(8):1768-1777
pubmed: 30030507
J Immunother. 2002 Mar-Apr;25(2):139-51
pubmed: 12074044
PLoS One. 2016 Jun 08;11(6):e0156321
pubmed: 27276051
MAbs. 2012 Mar-Apr;4(2):226-32
pubmed: 22453098
J Exp Med. 1965 Mar 1;121:439-62
pubmed: 14270243
J Urol. 2012 Nov;188(5):1712-8
pubmed: 22998907
Immunol Rev. 2016 Mar;270(1):152-64
pubmed: 26864110
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11782-7
pubmed: 22753489
Biomedicines. 2018 Jun 20;6(2):null
pubmed: 29925790
Cancer Sci. 2009 Aug;100(8):1359-65
pubmed: 19459847
BMC Biol. 2010 Feb 04;8:12
pubmed: 20132533
Cancer Res. 1988 Feb 1;48(3):589-601
pubmed: 3335022
Springerplus. 2015 Apr 08;4:168
pubmed: 25883890
Science. 1998 Oct 2;282(5386):121-5
pubmed: 9756476
Exp Cell Res. 1999 Nov 1;252(2):243-9
pubmed: 11501563
Nat Med. 2016 Feb;22(2):210-6
pubmed: 26752517
Eur J Cancer. 2003 Apr;39(6):718-27
pubmed: 12651195
Gene Ther. 2002 Aug;9(15):1049-53
pubmed: 12101437
Clin Cancer Res. 2016 Jul 1;22(13):3286-97
pubmed: 26861458
Int J Cancer. 1994 Jul 1;58(1):102-7
pubmed: 8014005
Curr Drug Targets. 2009 Feb;10(2):158-75
pubmed: 19199912
Oncoimmunology. 2015 Jul 1;4(9):e1036213
pubmed: 26405603
Curr Opin Cell Biol. 2006 Oct;18(5):565-71
pubmed: 16919437
J Immunol. 2001 Aug 1;167(3):1222-9
pubmed: 11466337
Nat Rev Cancer. 2006 Jul;6(7):559-65
pubmed: 16794638
J Immunol. 1997 Mar 15;158(6):2680-8
pubmed: 9058801
Biochem Pharmacol. 2014 Feb 1;87(3):410-23
pubmed: 24269628
Nat Med. 1996 Sep;2(9):979-84
pubmed: 8782454
Immunotherapy. 2015;7(8):883-2
pubmed: 26314314
Mol Immunol. 2019 Mar;107:44-53
pubmed: 30658247
Int J Cancer. 1995 May 16;61(4):497-501
pubmed: 7759155
Biochem J. 2000 Mar 1;346 Pt 2:519-28
pubmed: 10677374
J Vis Exp. 2010 Feb 25;(36):null
pubmed: 20186119
J Immunother. 2009 May;32(4):341-52
pubmed: 19342971
J Mol Recognit. 2005 Mar-Apr;18(2):119-38
pubmed: 15565717
J Immunol. 1998 Aug 15;161(4):1758-64
pubmed: 9712041
J Immunol. 2012 Jun 15;188(12):6119-26
pubmed: 22586033